Cell Reports (Oct 2019)

ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma

  • Swati Srivastava,
  • Nishanth Belugali Nataraj,
  • Arunachalam Sekar,
  • Soma Ghosh,
  • Chamutal Bornstein,
  • Diana Drago-Garcia,
  • Lee Roth,
  • Donatella Romaniello,
  • Ilaria Marrocco,
  • Eyal David,
  • Yuval Gilad,
  • Mattia Lauriola,
  • Ron Rotkopf,
  • Adi Kimchi,
  • Yuya Haga,
  • Yasuo Tsutsumi,
  • Olivier Mirabeau,
  • Didier Surdez,
  • Andrei Zinovyev,
  • Olivier Delattre,
  • Heinrich Kovar,
  • Ido Amit,
  • Yosef Yarden

Journal volume & issue
Vol. 29, no. 1
pp. 104 – 117.e4

Abstract

Read online

Summary: The glucocorticoid receptor (GR) acts as a ubiquitous cortisol-dependent transcription factor (TF). To identify co-factors, we used protein-fragment complementation assays and found that GR recognizes FLI1 and additional ETS family proteins, TFs relaying proliferation and/or migration signals. Following steroid-dependent translocation of FLI1 and GR to the nucleus, the FLI1-specific domain (FLS) binds with GR and strongly enhances GR’s transcriptional activity. This interaction has functional consequences in Ewing sarcoma (ES), childhood and adolescence bone malignancies driven by fusions between EWSR1 and FLI1. In vitro, GR knockdown inhibited the migration and proliferation of ES cells, and in animal models, antagonizing GR (or lowering cortisol) retarded both tumor growth and metastasis from bone to lung. Taken together, our findings offer mechanistic rationale for repurposing GR-targeting drugs for the treatment of patients with ES. : The single oncogene of Ewing sarcoma (ES), a childhood cancer, encodes a FLI1 fusion protein. Srivastava et al. report physical interactions between the fusion protein and the glucocorticoid receptor. Drug-induced inhibition of these interactions retards the progression of ES in mouse models. Keywords: cancer therapy, Ewing sarcoma, glucocorticoid receptor, metastasis, protein-fragment complementation assay